Direct granting support of Protein Alternatives’ Seal of Excellence project by Community of Madrid
November 21st, 2023 ProAlt’s therapeutic project named ‘METASTCURE' that has obtained the ‘Seal of [...]
ProAlt’s project for development of anti-CDH17 second-generation antibodies receives funding from CDTI
January 27th, 2023 The collaborative project named ‘Preclinical development and evolution of second-generation antibodies [...]
CANCERKINE project receives funding from the Ministry of Science and Innovation
The project named CANCERKINE and title ‘Preclinical development of monoclonal antibodies against IL13Ra2 for [...]
PROALT selected by the European Innovation Council to pitch at the EIC Investor Day with CUF
PROALT has been selected by the European Innovation Council (EIC) to pitch its innovative [...]
PROALT participates in Anglonordic Life Science Conference 2022
Anti-CDH17 and anti-IL13Ra2 monoclonal antibodies developed by PROALT togheter with the Spanish Research Council [...]
ProAlt’s COO participates in a discussion panel at Asebio Investor Day 2022
PROTEIN ALTERNTIVES Chief Operating Officer Mr Juan Ignacio Imbaud has participated today in the second [...]